Summary
In a 2024 decision, the United States Supreme Court determined that the plaintiffs involved in the case did not possess Article III standing. This legal finding precluded them from challenging the Food and Drug Administration's (FDA) approval and subsequent regulatory modifications pertaining to mifepristone. Consequently, this ruling preserved the existing access to the medication, which is widely recognized as the abortion pill.
Summary
In a 2024 legal decision, the Court determined that the individuals who brought the case lacked the necessary legal standing, known as Article III standing, to challenge the Food and Drug Administration's approval and regulatory changes for mifepristone. This ruling had the effect of preserving access to the medication used for abortion.
Summary
In a 2024 court case, the Court determined that the individuals who brought the case did not have the legal authority to challenge the Food and Drug Administration's approval and regulations for mifepristone. This decision protected continued access to the medication used for abortion.
Summary
A court case happened in 2024. The court decided that the individuals who brought the case could not challenge how the FDA approved or changed rules for the medicine mifepristone. This decision meant that the abortion pill remained available.